To further reveal the contribution of ACC and ACLY to the prognosis of USP22-positive HCC patients, we examined the prognostic value of USP22, ACACA and ACLY in the TCGA HCC dataset of 332 patients (patients died within 3 months or followed up for less than 1 month were removed). The gene discussed is USP22; the disease is hepatocellular carcinoma.